









Markets
/
Stocks
/
nasdaq-ango
/

AngioDynamics Inc

ANGO

11.010USD

+0.180+1.66%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

451.34MMarket Cap

LossP/E TTM



AngioDynamics Inc

11.010

+0.180+1.66%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

17 / 207

Overall Ranking

77 / 4721

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

18.250

Target Price

+68.51%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

AngioDynamics, Inc. is a transformative medical technology company. The Company is focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients. It designs, manufactures, and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Its devices are generally used in minimally invasive, image-guided procedures. Its segments include Med Tech and Med Device. Its product categories include oncology, venous therapies, vascular interventions, and ports. Its oncology products include Model 1500X RF Generator, IsoLoc Endorectal Balloon, Habib 4X Laparoscopic Bipolar Resection Device, Habib 4X Bipolar Resection Device, and Alatus. Its venous therapies include VenaCure EVLT 1470 Pro Laser, VenaCure EVLT System, VenaCure EVLT Procedure Packs, and others.

Undervalued

The company’s latest PE is -13.23, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 40.10M shares, decreasing 14.83% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.49M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.36.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 7.92, which is higher than the Healthcare Equipment & Supplies industry's average of 7.32. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 80.16M, representing a year-over-year increase of 12.93%, while its net profit experienced a year-over-year increase of 55.02%.

Score

Industry at a Glance

Previous score

7.92

Change



Financials

6.01

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

5.83

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.77

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 1.20, which is lower than the Healthcare Equipment & Supplies industry's average of 2.00. Its current P/E ratio is -13.02, which is -88.40% below the recent high of -1.51 and 8.34% above the recent low of -11.93.

Score

Industry at a Glance

Previous score

1.20

Change

1.6

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 17/207

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 8.50, which is higher than the Healthcare Equipment & Supplies industry's average of 7.70. The average price target for AngioDynamics Inc is 16.50, with a high of 24.00 and a low of 16.00.

Score

Industry at a Glance

Previous score

8.50

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

18.250

Target Price

+68.51%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

118

Total

Median

Average

Company name

Ratings

Analysts

AngioDynamics Inc

ANGO

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Zimmer Biomet Holdings Inc

ZBH

Dexcom Inc

DXCM

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 9.16, which is higher than the Healthcare Equipment & Supplies industry's average of 6.45. Sideways: Currently, the stock price is trading between the resistance level at 11.72 and the support level at 9.34, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.16

Change

0.08

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.013

Neutral

RSI(14)

69.660

Neutral

STOCH(KDJ)(9,3,3)

67.586

Buy

ATR(14)

0.339

High Vlolatility

CCI(14)

86.809

Neutral

Williams %R

9.678

Overbought

TRIX(12,20)

0.762

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

10.694

Buy

MA10

10.801

Buy

MA20

10.411

Buy

MA50

9.499

Buy

MA100

9.671

Buy

MA200

9.774

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.89. The latest institutional shareholding proportion is 98.69%, representing a quarter-over-quarter increase of 3.13%. The largest institutional shareholder is The Vanguard, holding a total of 2.49M shares, representing 6.13% of shares outstanding, with 8.58% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Divisadero Street Capital Management, LP

2.14M

+122.60%

BlackRock Institutional Trust Company, N.A.

3.06M

-5.44%

Systematic Financial Management, L.P.

2.50M

-0.94%

The Vanguard Group, Inc.

Star Investors

2.49M

+8.72%

Millennium Management LLC

1.24M

-42.68%

Point72 Asset Management, L.P.

Star Investors

928.66K

Armistice Capital LLC

2.09M

+140.14%

Segall Bryant & Hamill, LLC

1.38M

-2.17%

Dimensional Fund Advisors, L.P.

1.17M

-21.70%

Clemmer James C

929.61K

+2.20%

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 4.82, which is higher than the Healthcare Equipment & Supplies industry's average of 3.87. The company's beta value is 0.77. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.